&w=3840&q=100)
Alembic Pharmaceuticals up 2% as arm acquires Utility Therapeutics; details
SI Reporter New Delhi
Alembic Pharmaceuticals share price: Pharmaceuticals company Alembic Pharmaceuticals shares were trading higher on Thursday, July 3, 2025, with the scrip rising up to 2.05 per cent to hit an intraday high of ₹1,010 per share.
At 11:00 AM, Alembic Pharmaceuticals share price continued to trade higher, up about 1 per cent at ₹998.95. In comparison, BSE Sensex was trading 0.33 per cent higher at 83,688.57 levels.
Why did Alembic Pharmaceuticals share price rise today?
Alembic Pharmaceuticals share price rose after the company announced that its wholly-owned subsidiary, Alembic Pharmaceuticals Inc., has acquired Utility Therapeutics Ltd. for approximately $12 million.
In an exchange filing, Alembic Pharmaceuticals said, 'We are pleased to inform you that Alembic Pharmaceuticals Inc., wholly-owned subsidiary of Alembic Pharmaceuticals Limited, has acquired Utility Therapeutics Ltd.'
Utility Therapeutics is a pharmaceutical development company specialising in treatments for urinary tract infections (UTIs). The company is currently working on two key products. The first, Pivya, is already approved by the US Food and Drug Administration (FDA) for the treatment of uncomplicated UTIs in the US market. The second, MEC, is under development and aims to address the treatment of complicated UTIs. As a product development-focused company, Utility Therapeutics has reported minimal turnover over the past three years.
Alembic Pharmaceuticals said that the acquisition will be finalised in approximately 30 days.
The acquisition will allow the company to market the USFDA approved product and underdevelopment product owned by the Utility in the USA. Track Stock Market LIVE Updates
Alembic Pharmaceuticals Q4 results
Alembic Pharmaceuticals reported a 12 per cent year-on-year (Y-o-Y) decline in net profit in the March quarter of FY25 (Q4FY25), at ₹157 crore, despite a 17 per cent rise in net sales to ₹1,770 crore.
Ebitda grew 9 per cent to ₹286 crore, with the margin at 16 per cent, while profit before tax increased 5 per cent to ₹192 crore. READ MORE
About Alembic Pharmaceuticals
Alembic Pharmaceuticals is one of India's leading pharmaceutical companies, with a legacy dating back to 1907.
Headquartered in Vadodara, Gujarat, the company has established a strong global footprint through its fully integrated operations encompassing research, development, manufacturing, and marketing of pharmaceutical products.
A publicly listed entity, Alembic Pharmaceuticals is widely recognised for its extensive portfolio of generic drugs, supported by cutting-edge R&D facilities and approvals from major regulatory bodies, including the USFDA.
Its manufacturing facilities are located in Gujarat and Sikkim, while R&D centres in Vadodara, Hyderabad, and New Jersey drive innovation and development.
Alembic's global reach is further strengthened by its subsidiaries, Alembic Pharmaceuticals Inc. and Alembic Global Holding SA, positioning the company as a trusted provider of both branded and generic medicines worldwide.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Print
11 hours ago
- The Print
Stock markets muscle through intense volatility amid buying rush in heavyweights
The 50-share NSE Nifty inched up by 55.70 points or 0.22 per cent to 25,461. After oscillating between highs and lows in intra-day trade, the 30-share BSE Sensex ended 193.42 points or 0.23 per cent higher at 83,432.89. During the day, it hit a high of 83,477.86 and a low of 83,015.83, gyrating 462.03 points. Mumbai, Jul 4 (PTI) Benchmark indices Sensex and Nifty ended higher on Friday in a highly volatile trade amid a buying rush in banking and other bellwether stocks on the back of a rally in the US markets. From the Sensex firms, Bajaj Finance, Infosys, Hindustan Unilever, ICICI Bank, HCL Tech, UltraTech Cement, Bajaj Finserv, State Bank of India, Tata Consultancy Services, Reliance Industries, Axis Bank and Larsen & Toubro were among the major gainers. However, Trent, Tata Steel, Tech Mahindra and Maruti were among the laggards. 'The tone was negative in the first half; however, a decent recovery in heavyweight stocks pared all the losses as the day progressed, helping the index close near the day's high at the 25,461 level. 'With all eyes on the impending US-India trade deal as the tariff deadline approaches, participants are hopeful for a favourable outcome, which could provide the much-needed trigger for the next leg of the market up move,' Ajit Mishra – SVP, Research, Religare Broking Ltd, said. The BSE midcap gauge went up by 0.23 per cent and smallcap index climbed marginally by 0.17 per cent. Among BSE sectoral indices, oil & gas jumped 1.26 per cent, energy (0.90 per cent), realty (0.87 per cent), IT (0.67 per cent), healthcare (0.64 per cent), BSE Focused IT (0.65 per cent) and teck (0.52 per cent). Metal, telecommunication, auto, consumer discretionary and commodities were the laggards. As many as 2,261 stocks advanced while 1,788 declined and 140 remained unchanged on the BSE. 'The Indian market is experiencing a pause as investors adopt a wait-and-watch strategy ahead of the impending US tariff deadline with mixed global cues. Ongoing FII outflows reflect a risk-off approach, while DII inflows are offering partial support. 'Following the recent rally, main indices are hovering near peak valuation levels, limiting further upside, which is highly dependent on Q1 earnings and details of the trade deal,' Vinod Nair, Head of Research, Geojit Investments Limited, said. In Asian markets, Japan's Nikkei 225 index and Shanghai's SSE Composite index settled higher while South Korea's Kospi and Hong Kong's Hang Seng ended lower. European markets were trading in the negative territory. The US markets ended in the positive territory on Thursday. Global oil benchmark Brent crude dropped 1.03 per cent to USD 68.03 a barrel. Meanwhile, markets regulator Sebi has barred US-based Jane Street Group from the securities markets and directed the group to disgorge unlawful gains of Rs 4,843 crore for allegedly manipulating stock indices through positions taken in derivatives segment. This could be the highest disgorgement amount ever directed by the Securities and Exchange Board of India (Sebi). Foreign Institutional Investors (FIIs) offloaded equities worth Rs 1,481.19 crore on Thursday, according to exchange data. Domestic Institutional Investors (DIIs) bought stocks worth Rs 1,333.06 crore. On Thursday, the Sensex dropped by 170.22 points or 0.20 per cent to settle at 83,239.47. The Nifty declined by 48.10 points or 0.19 per cent to 25,405.30. 'Indian equity markets opened on a flat note Friday as investors remained cautious ahead of a potential India–US trade agreement and digested regulatory action against a major global trading entity. Both indices dipped during mid-session but recovered to end on a positive note…,' Gaurav Garg, Analyst, Lemonn Markets Desk, said. On the weekly front, the BSE benchmark gauge dropped 626.01 points or 0.74 per cent, and the Nifty declined 176.8 points or 0.68 per cent. PTI SUM HVA This report is auto-generated from PTI news service. ThePrint holds no responsibility for its content.
Business Standard
14 hours ago
- Business Standard
INR gains further ground at around 1-month high
The Indian rupee appreciated 16 paise to close at an over one-month high of 85.39 (provisional) against the US dollar on Friday, tracking a decline in the American currency in the overseas market and a weak tone in crude oil prices. Besides, rupee alongside other Asian currencies, gained ground on renewed hopes of trade deals with the US. US President Donald Trump announced a trade agreement with Vietnam, and that injected a dose of optimism that perhaps more such agreements could be in the pipeline before the crucial July 9 deadline. Meanwhile, the benchmark 30-share BSE Sensex ended the session up 193.42 points, or 0.23 percent, at 83,432.89, after having hit a low of 83,015.83 during intraday trade. The broader NSE Nifty index fell to 25,331.65 before reversing course to close up 55.70 points, or 0.22 percent, at 25,461 on optimism about India's upcoming trade deal with the United States.
Mint
16 hours ago
- Mint
Small-cap stock under ₹50 hits 52-week high logging intraday gain of 14%. Do you own?
Small-cap stock under ₹ 50: Sindhu Trade Links share price jumped as much as 14 per cent, hitting 52-week on Friday, July 4. The small-cap stock opened at ₹ 30.22 apiece in the early morning session, as compared to previous close of ₹ 29.95. Sindhu Trade Links share price ascended over 31 per cent in past five trading sessions and over 54 per cent in a month. The small-cap stock has given significant returns of up to 65 per cent in last one year. Sindhu Trade's net sales declined to ₹ 134.22 crore in March 2025, a decrease of 7.61% compared to ₹ 145.27 crore in March 2024. The company reported a net loss of ₹ 7.31 crore in March 2025, a sharp drop of 140.51% from a profit of ₹ 18.03 crore in the same quarter last year. EBITDA fell significantly to ₹ 1.89 crore in March 2025, down 93.61% from ₹ 29.59 crore recorded in March 2024. The stock rallied amid rising market sentiments on Friday. India's benchmark indices Sensex and Nifty opened slightly higher on Friday, despite lingering uncertainty surrounding U.S. President Donald Trump's trade deal deadline scheduled for next week. The BSE Sensex rose by 53 points, or 0.06%, to reach 83,291, while the Nifty50 advanced 10 points, or 0.04%, to 25,415 in early trade. Among the Sensex constituents, Bajaj Finance, BEL, Bajaj Finserv, HUL, and HDFC Bank opened on a positive note, gaining as much as 2.2%. In contrast, Trent, Tech Mahindra, Tata Steel, and M&M registered losses. "There are no triggers to break the 25200-25800 Nifty range immediately. Even while trading within this range the market is resilient. This resilience is supported externally by the strength of the mother market US where S&P 500 and Nasdaq are at record highs and domestically by the strong and sustained flows into the market, which has made DIIs sustained buyers in the market. The cap to the upside of the range is put by the tepid earnings growth and expectations of modest earnings growth in FY26. Investors should watch for possible changes in the earnings growth trajectory, the indications of which will be available in the Q1 results, which will start coming soon. Outperformances in results are likely to be company-specific rather than sector-specific. For instance autos are likely to report modest numbers, but TVS, Eicher and M&M can deliver better than industry numbers. Similarly in financials Bajaj Finance and Sriram Finance may outperform. Therefore, market action is likely to be stock-specific," said VK Vijayakumar, Chief Investment Strategist, Geojit Investments Limited.
